{
  "DOI": "10.1007/s10689-022-00314-z",
  "ISSN": [
    "1389-9600",
    "1573-7292"
  ],
  "URL": "http://dx.doi.org/10.1007/s10689-022-00314-z",
  "abstract": "\u003cjats:title\u003eAbstract\u003c/jats:title\u003e\u003cjats:p\u003eAn inherited single nucleotide variant (SNV) in the 5′UTR of the \u003cjats:italic\u003eBRCA1\u003c/jats:italic\u003e gene c.-107A \u0026gt; T was identified to be related to \u003cjats:italic\u003eBRCA1\u003c/jats:italic\u003e promoter hypermethylation and a hereditary breast and ovarian cancer phenotype in two UK families. We investigated whether this \u003cjats:italic\u003eBRCA1\u003c/jats:italic\u003e variant was also present in a Dutch cohort of breast and ovarian cancer patients with tumor \u003cjats:italic\u003eBRCA1\u003c/jats:italic\u003e promoter hypermethylation. We selected all breast and ovarian cancer cases that tested positive for tumor \u003cjats:italic\u003eBRCA1\u003c/jats:italic\u003e promoter hypermethylation at the Netherlands Cancer Institute and Sanger sequenced the specific mutation in the tumor DNA. In total, we identified 193 tumors with \u003cjats:italic\u003eBRCA1\u003c/jats:italic\u003e promoter hypermethylation in 178 unique patients. The wild-type allele was identified in 100% (193/193) of sequenced tumor samples. In a large cohort of 178 patients, none had tumors harboring the previously identified c.-107A \u0026gt; T SNV in \u003cjats:italic\u003eBRCA1\u003c/jats:italic\u003e. We therefore can conclude that the germline SNV is not pervasive in patients with tumor \u003cjats:italic\u003eBRCA1\u003c/jats:italic\u003e promoter hypermethylation.\u003c/jats:p\u003e",
  "alternative-id": [
    "314"
  ],
  "assertion": [
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Received",
      "name": "received",
      "order": 1,
      "value": "17 February 2022"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Accepted",
      "name": "accepted",
      "order": 2,
      "value": "2 June 2022"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "First Online",
      "name": "first_online",
      "order": 3,
      "value": "16 September 2022"
    },
    {
      "group": {
        "label": "Declarations",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 1
    },
    {
      "group": {
        "label": "Conflict of interest",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 2,
      "value": "SCL reports grants from ZonMw, the Dutch Cancer Society, and A Sister’s Hope during the conduct of the study. SCL is an advisory board member for Cergentis, and IBM, and received institutional research support from Agendia, AstraZeneca, Eurocept-pharmaceuticals, Genentech, Novartis, Pfizer, Roche, Tesaro, and Immunomedics. In addition, SCL received institutional non-financial support from AstraZeneca, Genentech, Novartis, Roche, Tesaro, and Immunomedics and institutional educational financial support from Bayer and Daiichi-Sankyo outside of this study. All other authors declare no competing interest."
    },
    {
      "group": {
        "label": "Ethical approval",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 3,
      "value": "The study was approved by the institutional research board of the Netherlands Cancer Institute (IRBdm19-106). All (retrospective) medical data/biospecimen studies at the Netherlands Cancer Institute have been executed pursuant to Dutch legislation and international standards. Prior to 25 May 2018, national legislation on data protection applied, as well as the International Guideline on Good Clinical Practice. From 25 May 2019 we also adhere to the GDPR. Within this framework, patients are informed and have always had the opportunity to object or actively consent to the (continued) use of their personal data \u0026 biospecimens in research. Hence, the procedures comply both with (inter-) national legislative and ethical standards. Patients included in clinical trials have given written informed consent."
    }
  ],
  "author": [
    {
      "affiliation": [],
      "family": "de Jong",
      "given": "Vincent M. T.",
      "sequence": "first"
    },
    {
      "affiliation": [],
      "family": "Pruntel",
      "given": "Roelof",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Steenbruggen",
      "given": "Tessa G.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Bleeker",
      "given": "Fonnet E.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Nederlof",
      "given": "Petra",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Hogervorst",
      "given": "Frans B. L.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "linn",
      "given": "Sabine C.",
      "sequence": "additional"
    }
  ],
  "container-title": [
    "Familial Cancer"
  ],
  "content-domain": {
    "crossmark-restriction": false,
    "domain": [
      "link.springer.com"
    ]
  },
  "created": {
    "date-parts": [
      [
        2022,
        9,
        16
      ]
    ],
    "date-time": "2022-09-16T09:02:41Z",
    "timestamp": 1663318961000
  },
  "deposited": {
    "date-parts": [
      [
        2023,
        3,
        16
      ]
    ],
    "date-time": "2023-03-16T09:21:27Z",
    "timestamp": 1678958487000
  },
  "indexed": {
    "date-parts": [
      [
        2023,
        9,
        25
      ]
    ],
    "date-time": "2023-09-25T18:26:16Z",
    "timestamp": 1695666376764
  },
  "is-referenced-by-count": 1,
  "issn-type": [
    {
      "type": "print",
      "value": "1389-9600"
    },
    {
      "type": "electronic",
      "value": "1573-7292"
    }
  ],
  "issue": "2",
  "issued": {
    "date-parts": [
      [
        2022,
        9,
        16
      ]
    ]
  },
  "journal-issue": {
    "issue": "2",
    "published-print": {
      "date-parts": [
        [
          2023,
          4
        ]
      ]
    }
  },
  "language": "en",
  "license": [
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "tdm",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2022,
            9,
            16
          ]
        ],
        "date-time": "2022-09-16T00:00:00Z",
        "timestamp": 1663286400000
      }
    },
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "vor",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2022,
            9,
            16
          ]
        ],
        "date-time": "2022-09-16T00:00:00Z",
        "timestamp": 1663286400000
      }
    }
  ],
  "link": [
    {
      "URL": "https://link.springer.com/content/pdf/10.1007/s10689-022-00314-z.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://link.springer.com/article/10.1007/s10689-022-00314-z/fulltext.html",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://link.springer.com/content/pdf/10.1007/s10689-022-00314-z.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "member": "297",
  "page": "151-154",
  "prefix": "10.1007",
  "published": {
    "date-parts": [
      [
        2022,
        9,
        16
      ]
    ]
  },
  "published-online": {
    "date-parts": [
      [
        2022,
        9,
        16
      ]
    ]
  },
  "published-print": {
    "date-parts": [
      [
        2023,
        4
      ]
    ]
  },
  "publisher": "Springer Science and Business Media LLC",
  "reference": [
    {
      "DOI": "10.3322/caac.21166",
      "author": "R Siegel",
      "doi-asserted-by": "publisher",
      "first-page": "11",
      "journal-title": "CA Cancer J Clin",
      "key": "314_CR1",
      "unstructured": "Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11–30. https://doi.org/10.3322/caac.21166",
      "volume": "63",
      "year": "2013"
    },
    {
      "DOI": "10.1054/bjoc.2000.1407",
      "author": "BAJ Ponder",
      "doi-asserted-by": "publisher",
      "first-page": "1301",
      "journal-title": "Br J Cancer",
      "key": "314_CR2",
      "unstructured": "Ponder BAJ, Pharoah PDP, Ponder BAJ et al (2000) Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer 83:1301–1308. https://doi.org/10.1054/bjoc.2000.1407",
      "volume": "83",
      "year": "2000"
    },
    {
      "DOI": "10.1080/0284186X.2018.1529428",
      "author": "C Wendt",
      "doi-asserted-by": "publisher",
      "first-page": "135",
      "journal-title": "Acta Oncol",
      "key": "314_CR3",
      "unstructured": "Wendt C, Margolin S (2019) Identifying breast cancer susceptibility genes—a review of the genetic background in familial breast cancer. Acta Oncol 58:135–146. https://doi.org/10.1080/0284186X.2018.1529428",
      "volume": "58",
      "year": "2019"
    },
    {
      "DOI": "10.1056/nejmoa1913948",
      "author": "L Dorling",
      "doi-asserted-by": "publisher",
      "first-page": "428",
      "journal-title": "N Engl J Med",
      "key": "314_CR4",
      "unstructured": "Dorling L, Carvalho S, Allen J et al (2021) Breast cancer risk genes —association analysis in more than 113,000 women. N Engl J Med 384:428–439. https://doi.org/10.1056/nejmoa1913948",
      "volume": "384",
      "year": "2021"
    },
    {
      "DOI": "10.1056/NEJMsr1501341",
      "author": "DF Easton",
      "doi-asserted-by": "publisher",
      "first-page": "2243",
      "journal-title": "N Engl J Med",
      "key": "314_CR5",
      "unstructured": "Easton DF, Pharoah PDP, Antoniou AC et al (2015) Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med 372:2243–2257. https://doi.org/10.1056/NEJMsr1501341",
      "volume": "372",
      "year": "2015"
    },
    {
      "DOI": "10.1001/jamaoncol.2021.6744",
      "author": "N Mavaddat",
      "doi-asserted-by": "publisher",
      "first-page": "1",
      "journal-title": "JAMA Oncol",
      "key": "314_CR6",
      "unstructured": "Mavaddat N, Dorling L, Carvalho S et al (2022) Pathology of tumors associated with pathogenic germline variants in 9 breast cancer susceptibility genes. JAMA Oncol 8:1–11. https://doi.org/10.1001/jamaoncol.2021.6744",
      "volume": "8",
      "year": "2022"
    },
    {
      "DOI": "10.1056/NEJMoa064522",
      "author": "MP Hitchins",
      "doi-asserted-by": "publisher",
      "first-page": "697",
      "journal-title": "N Engl J Med",
      "key": "314_CR7",
      "unstructured": "Hitchins MP, Wong JJL, Suthers G et al (2007) Inheritance of a cancer-associated MLH1 germ-line epimutation. N Engl J Med 356:697–705. https://doi.org/10.1056/NEJMoa064522",
      "volume": "356",
      "year": "2007"
    },
    {
      "DOI": "10.1038/s41467-018-03058-6",
      "author": "JE Joo",
      "doi-asserted-by": "publisher",
      "journal-title": "Nat Commun",
      "key": "314_CR8",
      "unstructured": "Joo JE, Dowty JG, Milne RL et al (2018) Heritable DNA methylation marks associated with susceptibility to breast cancer. Nat Commun. https://doi.org/10.1038/s41467-018-03058-6",
      "year": "2018"
    },
    {
      "DOI": "10.1186/s13148-022-01239-1",
      "author": "N Marino",
      "doi-asserted-by": "publisher",
      "first-page": "1",
      "journal-title": "Clin Epigenetics",
      "key": "314_CR9",
      "unstructured": "Marino N, German R, Podicheti R et al (2022) Aberrant epigenetic and transcriptional events associated with breast cancer risk. Clin Epigenetics 14:1–17. https://doi.org/10.1186/s13148-022-01239-1",
      "volume": "14",
      "year": "2022"
    },
    {
      "DOI": "10.1038/srep17869",
      "author": "L Zhang",
      "doi-asserted-by": "publisher",
      "journal-title": "Sci Rep",
      "key": "314_CR10",
      "unstructured": "Zhang L, Long X (2015) Association of BRCA1 promoter methylation with sporadic breast cancers: evidence from 40 studies. Sci Rep. https://doi.org/10.1038/srep17869",
      "year": "2015"
    },
    {
      "DOI": "10.1038/bjc.2013.144",
      "author": "EH Lips",
      "doi-asserted-by": "publisher",
      "first-page": "2172",
      "journal-title": "Br J Cancer",
      "key": "314_CR11",
      "unstructured": "Lips EH, Mulder L, Oonk A et al (2013) Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers. Br J Cancer 108:2172–2177. https://doi.org/10.1038/bjc.2013.144",
      "volume": "108",
      "year": "2013"
    },
    {
      "DOI": "10.3390/cancers12040828",
      "author": "W Jacot",
      "doi-asserted-by": "publisher",
      "journal-title": "Cancers",
      "key": "314_CR12",
      "unstructured": "Jacot W, Lopez-Crapez E, Mollevi C et al (2020) BRCA1 promoter hypermethylation is associated with good prognosis and chemosensitivity in triple-negative breast cancer. Cancers. https://doi.org/10.3390/cancers12040828",
      "year": "2020"
    },
    {
      "DOI": "10.1093/jnci/92.7.564",
      "author": "M Esteller",
      "doi-asserted-by": "publisher",
      "first-page": "564",
      "issue": "7",
      "journal-title": "J Natl Cancer Inst",
      "key": "314_CR13",
      "unstructured": "Esteller M, Silva JM, Dominguez G et al (2000) Promoter hypermethylation and brca1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 92(7):564–569",
      "volume": "92",
      "year": "2000"
    },
    {
      "DOI": "10.1016/j.critrevonc.2018.05.008",
      "author": "S Vos",
      "doi-asserted-by": "publisher",
      "first-page": "29",
      "journal-title": "Crit Rev Oncol Hematol",
      "key": "314_CR14",
      "unstructured": "Vos S, van Diest PJ, Moelans CB (2018) A systematic review on the frequency of BRCA promoter methylation in breast and ovarian carcinomas of BRCA germline mutation carriers: mutually exclusive, or not? Crit Rev Oncol Hematol 127:29–41",
      "volume": "127",
      "year": "2018"
    },
    {
      "DOI": "10.1093/annonc/mdq468",
      "author": "EH Lips",
      "doi-asserted-by": "publisher",
      "first-page": "870",
      "journal-title": "Ann Oncol",
      "key": "314_CR15",
      "unstructured": "Lips EH, Mulder L, Hannemann J et al (2011) Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy. Ann Oncol 22:870–876. https://doi.org/10.1093/annonc/mdq468",
      "volume": "22",
      "year": "2011"
    },
    {
      "DOI": "10.1136/jmedgenet-2017-104584",
      "author": "DG Evans",
      "doi-asserted-by": "publisher",
      "first-page": "674",
      "journal-title": "J Med Genet",
      "key": "314_CR16",
      "unstructured": "Evans DG, Harkness EF, Plaskocinska I et al (2017) Pathology update to the manchester scoring system based on testing in over 4000 families. J Med Genet 54:674–681. https://doi.org/10.1136/jmedgenet-2017-104584",
      "volume": "54",
      "year": "2017"
    },
    {
      "DOI": "10.1016/j.ajhg.2018.07.002",
      "author": "DGR Evans",
      "doi-asserted-by": "publisher",
      "first-page": "213",
      "journal-title": "Am J Hum Genet",
      "key": "314_CR17",
      "unstructured": "Evans DGR, van Veen EM, Byers HJ et al (2018) A dominantly inherited 5′UTR variant causing methylation-associated silencing of BRCA1 as a cause of breast and ovarian cancer. Am J Hum Genet 103:213–220. https://doi.org/10.1016/j.ajhg.2018.07.002",
      "volume": "103",
      "year": "2018"
    },
    {
      "DOI": "10.1007/s10689-020-00175-4",
      "author": "A Laner",
      "doi-asserted-by": "publisher",
      "first-page": "211",
      "journal-title": "Fam Cancer",
      "key": "314_CR18",
      "unstructured": "Laner A, Benet-Pages A, Neitzel B, Holinski-Feder E (2020) Analysis of 3297 individuals suggests that the pathogenic germline 5′-UTR variant BRCA1 c.-107A \u003e T is not common in south-east Germany. Fam Cancer 19:211–213. https://doi.org/10.1007/s10689-020-00175-4",
      "volume": "19",
      "year": "2020"
    },
    {
      "DOI": "10.6004/jnccn.2021.0001",
      "author": "MB Daly",
      "doi-asserted-by": "publisher",
      "first-page": "77",
      "journal-title": "J Natl Compr Cancer Netw",
      "key": "314_CR19",
      "unstructured": "Daly MB, Pal T, Berry MP et al (2021) Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 19:77–102. https://doi.org/10.6004/jnccn.2021.0001",
      "volume": "19",
      "year": "2021"
    },
    {
      "DOI": "10.1002/gcc.20833",
      "author": "SA Joosse",
      "doi-asserted-by": "publisher",
      "first-page": "71",
      "journal-title": "Genes Chromosom Cancer",
      "key": "314_CR20",
      "unstructured": "Joosse SA, Brandwijk KIM, Mulder L et al (2011) Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors. Genes Chromosom Cancer 50:71–81. https://doi.org/10.1002/gcc.20833",
      "volume": "50",
      "year": "2011"
    },
    {
      "DOI": "10.1186/bcr3655",
      "author": "MA Vollebergh",
      "doi-asserted-by": "publisher",
      "first-page": "1",
      "journal-title": "Breast Cancer Res",
      "key": "314_CR21",
      "unstructured": "Vollebergh MA, Lips EH, Nederlof PM et al (2014) Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy. Breast Cancer Res 16:1–13. https://doi.org/10.1186/bcr3655",
      "volume": "16",
      "year": "2014"
    },
    {
      "DOI": "10.1016/j.molonc.2015.03.002",
      "author": "PC Schouten",
      "doi-asserted-by": "publisher",
      "first-page": "1274",
      "journal-title": "Mol Oncol",
      "key": "314_CR22",
      "unstructured": "Schouten PC, Grigoriadis A, Kuilman T et al (2015) Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platforms. Mol Oncol 9:1274–1286. https://doi.org/10.1016/j.molonc.2015.03.002",
      "volume": "9",
      "year": "2015"
    },
    {
      "DOI": "10.1038/s41586-020-2308-7",
      "author": "KJ Karczewski",
      "doi-asserted-by": "publisher",
      "first-page": "434",
      "journal-title": "Nature",
      "key": "314_CR23",
      "unstructured": "Karczewski KJ, Francioli LC, Tiao G et al (2020) The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581:434–443. https://doi.org/10.1038/s41586-020-2308-7",
      "volume": "581",
      "year": "2020"
    }
  ],
  "reference-count": 23,
  "references-count": 23,
  "resource": {
    "primary": {
      "URL": "https://link.springer.com/10.1007/s10689-022-00314-z"
    }
  },
  "score": 0,
  "short-container-title": [
    "Familial Cancer"
  ],
  "source": "Crossref",
  "title": [
    "Identifying the BRCA1 c.-107A \u0026gt; T variant in Dutch patients with a tumor BRCA1 promoter hypermethylation"
  ],
  "type": "journal-article",
  "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy",
  "volume": "22"
}